Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Goodwill (2023 - 2025)

Historic Goodwill for Cartesian Therapeutics (RNAC) over the last 3 years, with Q3 2025 value amounting to $48.2 million.

  • Cartesian Therapeutics' Goodwill changed 0.0% to $48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $48.2 million for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Goodwill is $48.2 million, which was down 0.0% from $48.2 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Goodwill peaked at $48.2 million during Q4 2023, and registered a low of $48.2 million during Q4 2023.
  • For the 3-year period, Cartesian Therapeutics' Goodwill averaged around $48.2 million, with its median value being $48.2 million (2023).
  • Examining YoY changes over the last 5 years, Cartesian Therapeutics' Goodwill showed a top increase of 0.0% in 2024 and a maximum decrease of 0.0% in 2024.
  • Cartesian Therapeutics' Goodwill (Quarter) stood at $48.2 million in 2023, then changed by 0.0% to $48.2 million in 2024, then changed by 0.0% to $48.2 million in 2025.
  • Its Goodwill stands at $48.2 million for Q3 2025, versus $48.2 million for Q2 2025 and $48.2 million for Q1 2025.